Driving engagement and growth across local and global networks
Contents

Message from the Chair 3
Message from the CEO 5
Our Board 6
Our Team 8
Our Interns 9
About BioMelbourne Network 10
Strategic Priorities 12
Events and Sponsorship 21
Member Testimonials 33

BioMelbourne Network acknowledges and pays respect to the Traditional Custodians of the land on which our network lives and works. We pay our respects to their Elders past, present and emerging. We recognise the strength of their connection to land, their culture and the value that their ways of knowing and understanding the world bring to our community. We acknowledge that Aboriginal and Torres Strait Islander people continue to live in spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.
I wish to begin my message by thanking our former Chair, Lusia Guthrie for her significant service and contribution to our Network over many years. She led a united and productive Board, and I look forward to leading our Board in the same vein. My thanks also to our members for entrusting me with this important role. I look forward to serving you.

I’m delighted that BioMelbourne Network continues to foster and grow an innovative, globally competitive healthtech industry in Victoria by increasing sector connectivity, partnering with Victorian authorities and advocating on behalf of our membership. Our industry significantly contributes to the Victorian economy through innovative research, health technology products and services, which create new jobs and benefit the wider community. Our Board and management team remain committed to our members and industry and implementing our exciting plans.

As a Board, it’s critical to protect the integrity of our organisation, understand our employees and members, and represent the needs of an evolving healthtech sector. As we have seen in the past two years, the COVID-19 pandemic has magnified the challenges that we face.

This year BioMelbourne Network pivoted again, providing hybrid events and then welcoming attendees in-person. I attended our first Non-Executive Directors’ lunch sponsored and led by KPMG, which was insightful and a welcome return to deep conversations with people.

However, the way we work has changed forever, with hybrid working practices being maintained - something we all have to adapt to.

Science, medicine, engineering and manufacturing are again firmly in the spotlight.

Resources, precincts and investment are being applied across the spectrum to position Victoria as a fully integrated research, manufacturing and supply ecosystem, despite the broader economic challenges, locally and globally.

As we look ahead, we have set our sights on new opportunities. The Victorian Government is significantly supporting our industry through the $2 billion Breakthrough Victoria Fund, an initiative to drive investment in translational research, innovation and commercialisation, and accelerate job creation and growth in health and life sciences, and advanced manufacturing. This Fund is expected to catalyse investment from other industry, university and government sources and create 15,700 new jobs over 10 years.

ANDHealth, Australia’s leading digital health commercialisation organisation, in partnership with the Victorian Government, recently received $2.4 million from the Australian Medtech Manufacturing Centre and Biotechnology Fund to create the Victorian Connected Health Innovation and Commercialisation Centre. This entity will drive the creation and commercialisation of digital and digitally enabled medical technology companies and raise Victoria’s profile as a leading centre for Australia’s connected health sector.

We head into 2023 with a progressive and diverse membership, and our Board and terrific management team will continue to be supportive and relevant.
Message from the Chair

We have seen major investments from industry, government and donors, with CSL committing to new laboratories and offices in its new headquarters in Parkville in 2023. The facility will foster collaborations between researchers and industry, and progress translation of new medicines.

Two biotech companies will set up mRNA research and manufacturing centres in Victoria – Moderna in mRNA vaccines and BioNTech in cutting-edge drug design. And Geoffrey Cumming has donated $250 million – the largest philanthropic investment in medical research in Australia – to establish a new Cumming Global Centre for Pandemic Therapeutics here.

As Chair and on behalf of our membership, I’m grateful for the continued support that BioMelbourne Network receives from the Victorian Government to launch new initiatives and provide reports and insights about the Victorian healthtech industry.

At BioMelbourne Network, we look forward to aligning our strategic plan and evolving to meet the needs of you, our members. We head into 2023 with a progressive and diverse membership, and our Board and terrific management team will continue to be supportive and relevant.

I wish to acknowledge and thank our Board of Directors for their significant experience, their generous spirit in which they give their time, knowledge, skills and insight to support the management team and our members.

I would like to personally thank Elane Zelcer (Deputy Chair), Amy Demediuik (Secretary and Public Officer), Theodora Elia-Adams (Treasurer), Tim Oldham, Keith McLean and our recently appointed Director Andrew Wear, for their commitment and support. As a Board, we continue to focus on the long-term sustainability of BioMelbourne Network and to identify how we can best support the growth of the Victorian healthtech industry.

In this Annual Report, our CEO, Jeff Malone, expands on his plans for BioMelbourne Network in 2023. Despite the pandemic, our membership numbers have increased. New collaborations are adding to revenues and the BioMelbourne Network team continues to expand to serve our members. Jeff’s commitment, leadership, enthusiasm and connectivity provide a strong foundation for ongoing success. His growing knowledge and passion for our sector, together with his can-do attitude are infectious, enabling him to set a challenging agenda for his team, who continue to deliver at pace.

The Board and I are immensely proud of our Network and want to acknowledge and sincerely thank our members, employees, stakeholders, sponsors and supporters. I thank you, our members, for your contribution and commitment to our industry. You are helping to ensure that BioMelbourne Network remains dynamic and continues to develop programs that support you and our sector.

David Herd
Chair
BioMelbourne Network is pleased to report that our position as the peak body in the Victorian healthtech industry is stronger than ever before.

During 2021-2022, BioMelbourne Network delivered outcomes aligned with our three-year strategic plan. We are transforming our Network into a more agile and responsive organisation and delivering value to our members as well as the broader Victorian ecosystem.

The increasing value proposition we provide, combined with our growing prominence in the sector across the state, throughout Australia and internationally, has seen a continued growth in membership, with some of the biggest names in industry coming on board over the past year.

BioMelbourne Network continues its evolution as the preferred source for insights into the healthtech sector, leading or participating in over eight working groups to address industry needs. Our role as a key advocate has expanded to include issues both large and small, so we can provide even more support to the sector in Victoria. While we remain a state-based industry not-for-profit association, we represent a significant portion of the healthtech sector. By collaborating closely with other state and national bodies, we are leveraging our strong advocacy position to support national issues wherever possible.

Our expansive events program continues thanks to the support of our membership along with the ongoing support of our sponsors and partners from the life sciences industry and Victorian Government.

We have adapted our offering, so our major events are now hybrid, resulting in a 61% increase in overall attendance year on year.

As part of our funded initiatives, we delivered Futuremap assessments of Victorian manufacturers, in partnership with Medtech Victoria, to assess their readiness to implement continuous change and Industry 4.0. We have also partnered with Global Victoria and produced a podcast series across seven key industry sectors to promote our strengths throughout Australia and overseas.

Throughout the year we have delivered additional value across the breadth of our ecosystem, to researchers, services providers, manufacturers, startups and the Victorian Government.

Our newly funded digital transformation initiatives are positioned to reimagine engagement in the life sciences industry. Our Wilam Life Sciences Industry Community allows connectivity and engagement throughout Australia and beyond, while our online event library will ensure that the value of our events program is available on demand.

I would like to thank all our members and sponsors for their support this year. I would especially like to thank the Victorian Government for their ongoing support of our events program and strategic initiatives.

Jeff Malone
Chief Executive Officer

Over the coming years, we foresee BioMelbourne Network playing an ever-increasing role within the Victorian ecosystem and expanding connections nationally and internationally.
Our Board

David Herd
Chair
(Nov 2021 – present)

David Herd has worked within the pharmaceutical industry for over 30 years, a period which has seen the industry environment and the science significantly change. He has been at the forefront of understanding, translating and strategically advising how to adjust to regulatory and legislative changes, ensuring that companies are able to access the market efficiently and serve their patients. David has held a number of Industry Association and Advisory roles representing the industry, including being part of the National Medicines Policy Expert Review Committee.

Amy Demediuk
Secretary/Public Officer

Amy is CSL Limited’s Associate General Counsel, Asia Pacific, Global R&D and Corporate Development. In her current role, Amy leads a global legal team supporting CSL’s early-stage research programs and collaborations right through to M&A activity, as well as a regional legal team supporting CSL’s commercial and manufacturing operations across Asia Pacific. Prior to joining CSL, Amy worked in a dedicated intellectual property commercialisation role at (then) ASX-listed Ipernica Limited and prior to that, in private corporate legal practice at Arnold Bloch Liebler. Amy holds a Bachelor of Laws and Masters of IP Law from the University of Melbourne, and a Graduate Diploma in Applied Corporate Governance from the Governance Institute.

Lusia Guthrie
Former Chair
(Retired Nov 2021)

Lusia has over 35 years’ experience in the pharmaceutical and bioscience industries. She is Chair of the Australian Lung Health Initiative, Chair of Neo-Bionica and Independent Director at WearOptimo. Lusia is a member of Industry Advisory Committees for the: Australian Regenerative Medicine Institute, Australian Institute for Machine Learning, and the Australian Medtech Manufacturing Centre.

Theodora Elia-Adams
Treasurer

Theodora holds a Bachelor of Commerce and Master of Taxation from the University of Melbourne and is a Chartered Accountant and member of the AICD. Theodora is an experienced board member and former Ernst & Young Partner, who brings valuable skills in governance, quality assurance, risk management, tax and financial management.

Dr Elane Zelcer
Deputy Chair

Elane is Director, BioConsult Pty Ltd and joined BioMelbourne Network’s Board in November 2019. She has more than 25 years’ experience in the healthtech sector, including director, executive management, management consulting and academic roles. Elane has worked with and advised SMEs, multinational companies, universities, CRCs, and Federal and State government committees. This includes guiding strategic decision-making, risk management, governance, capital raising and commercialisation. Much of this activity has involved the intersection between the research sector and business.

Dr Tim Oldham
Director

Tim is the Chief Executive Officer and Managing Director of AdAlta Ltd. Previous executive roles span more than 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He has been the Executive Leader at Tijan Ventures, CEO/MD of Cell Therapies Pty Ltd, President of Asia Pacific for Hospira Inc. and has held various European business development, strategic marketing and regional leadership roles with Mayne Pharma. Current Non-Executive Director roles include Acrux Ltd and Tim is a former Non-Executive Director of Respiri Ltd and Imunexus Ltd.

David Herd has worked within the pharmaceutical industry for over 30 years, a period which has seen the industry environment and the science significantly change. He has been at the forefront of understanding, translating and strategically advising how to adjust to regulatory and legislative changes, ensuring that companies are able to access the market efficiently and serve their patients. David has held a number of Industry Association and Advisory roles representing the industry, including being part of the National Medicines Policy Expert Review Committee.

Amy Demediuk is CSL Limited’s Associate General Counsel, Asia Pacific, Global R&D and Corporate Development. In her current role, Amy leads a global legal team supporting CSL’s early-stage research programs and collaborations right through to M&A activity, as well as a regional legal team supporting CSL’s commercial and manufacturing operations across Asia Pacific. Prior to joining CSL, Amy worked in a dedicated intellectual property commercialisation role at (then) ASX-listed Ipernica Limited and prior to that, in private corporate legal practice at Arnold Bloch Liebler. Amy holds a Bachelor of Laws and Masters of IP Law from the University of Melbourne, and a Graduate Diploma in Applied Corporate Governance from the Governance Institute.

Lusia Guthrie has over 35 years’ experience in the pharmaceutical and bioscience industries. She is Chair of the Australian Lung Health Initiative, Chair of Neo-Bionica and Independent Director at WearOptimo. Lusia is a member of Industry Advisory Committees for the: Australian Regenerative Medicine Institute, Australian Institute for Machine Learning, and the Australian Medtech Manufacturing Centre.

Theodora Elia-Adams holds a Bachelor of Commerce and Master of Taxation from the University of Melbourne and is a Chartered Accountant and member of the AICD. Theodora is an experienced board member and former Ernst & Young Partner, who brings valuable skills in governance, quality assurance, risk management, tax and financial management.

Dr Elane Zelcer is Director, BioConsult Pty Ltd and joined BioMelbourne Network’s Board in November 2019. She has more than 25 years’ experience in the healthtech sector, including director, executive management, management consulting and academic roles. Elane has worked with and advised SMEs, multinational companies, universities, CRCs, and Federal and State government committees. This includes guiding strategic decision-making, risk management, governance, capital raising and commercialisation. Much of this activity has involved the intersection between the research sector and business.

Dr Tim Oldham is the Chief Executive Officer and Managing Director of AdAlta Ltd. Previous executive roles span more than 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He has been the Executive Leader at Tijan Ventures, CEO/MD of Cell Therapies Pty Ltd, President of Asia Pacific for Hospira Inc. and has held various European business development, strategic marketing and regional leadership roles with Mayne Pharma. Current Non-Executive Director roles include Acrux Ltd and Tim is a former Non-Executive Director of Respiri Ltd and Imunexus Ltd.
Dr Keith McLean  
**Director**  
Keith was elected to the Board of Directors in November 2020. He has a PhD in industrial microbiology from the University of Aberdeen, Scotland. In July 2020, Keith retired as CSIRO Director of Manufacturing, a position he held since 2014. At CSIRO, Keith led 350+ scientists and engineers developing solutions for high-tech Australian manufacturing in biomedical, chemical and fibre, metals, and innovative manufacturing, with a focus on Australian and global companies.

Andrew Wear  
**Director**  
Andrew was appointed to the Board of Directors in February 2022. He is a senior Australian public servant and author. Currently City Economist and Director of Economic Development and International at the City of Melbourne, Andrew has extensive experience working for national and state governments. His last role was as Director of Innovation, Department of Jobs, Precincts and Regions, with the Victorian government. Andrew has degrees in politics, law, economics and public policy and is a graduate of the Senior Executive Fellows program at Harvard Kennedy School. He is a Victorian Fellow of the Institute of Public Administration Australia and a Graduate Member of the Australian Institute of Company Directors.

Our board comprises a diverse group of bright minds who bring their industry experience, skill and passion together to stimulate innovation and growth in the Victorian life sciences and health technology ecosystem. Members are at the heart of BioMelbourne Network and your interests guide our strategy, advocacy priorities and initiatives.

Amy Demediuk  
**Secretary/Public Officer, BioMelbourne Network Board**
Nicole Pitcher  
Office Manager  
Nicole joined BioMelbourne Network in 2003 and is the longest-serving staff member in our organisation. Her meticulous attention to detail, coordination of office management and relationships with members contributes to the ongoing success of BioMelbourne Network’s operations.

Emma Donnelly  
Strategic Project Manager  
Emma joined BioMelbourne Network in 2021 and brings more than 20 years of science communication, engagement and strategy experience to our organisation. She has worked for the Victorian Government, universities and not-for-profits. Emma has a passion for promoting engagement in science and supporting the healthtech sector to achieve this goal. Her engagement programs have won the Premier’s Science Awards and a Eureka Prize. Emma holds a Bachelor of Science, Post Graduate Diploma in Science and a Diploma from the University of Champagne-Ardenne.

Jeff Malone  
Chief Executive Officer  
Jeff Malone has more than 30 years’ experience in business, export market development, product translation and design, commercialisation and manufacturing. Before joining BioMelbourne Network in 2020, he led the largest contract medical device manufacturing facility in Australia. Jeff has held senior leadership roles in two of Victoria’s leading design and development firms and has a reputation for bringing stakeholders together to build commercial networks, broker innovation and advocate on behalf of the healthtech industry.

Vicky Jones  
Operations Manager  
Vicky joined BioMelbourne Network in 2014 after relocating from Malaysia. She has more than 18 years’ experience in event management, business development, marketing and client relations. While in Malaysia, Vicky worked as the Executive Director of the British Malaysian Chamber of Commerce and Assistant Project Director for the BMW Malaysian Open, a WTA international tennis tournament.

Vicky joined BioMelbourne Network in 2014 after relocating from Malaysia. She has more than 18 years’ experience in event management, business development, marketing and client relations. While in Malaysia, Vicky worked as the Executive Director of the British Malaysian Chamber of Commerce and Assistant Project Director for the BMW Malaysian Open, a WTA international tennis tournament.

James Masters  
Communications Officer (Until June 2022)  
James joined BioMelbourne Network in 2021. Originally from Perth, Western Australia, James holds a Bachelor of Commerce from Curtin University, where he majored in marketing and advertising. James brings a wealth of marketing and communications experience from his time working in the Australian, Canadian and the United Kingdom health and education sectors. Before joining BioMelbourne Network, James was Communications and Marketing Manager at the Australian Medical Association.

Jo O’Brien  
Events and Projects Manager  
Jo joined BioMelbourne Network in 2017 after a 12-year-long career as an underground resource geologist, working across Australia and abroad. Originally from New Zealand, Jo holds a Bachelor of Science from the University of Auckland, and a Diploma of Event Management from the College of Event Management, Melbourne. With a passion for science and corporate events, her career transition from outback Australia to Melbourne led Jo to her current role as Events and Projects Manager with BioMelbourne Network.

Jess Balk  
Digital Platform Manager  
Jess joined BioMelbourne Network in 2021. Since then, she has worked across communications and strategic projects before taking on her current role as Digital Platform Manager. Jess holds a Master of Biomedical and Health Sciences from Monash University and is enthusiastic about increasing engagement across the healthtech industry.

Jess joined BioMelbourne Network in 2021. Since then, she has worked across communications and strategic projects before taking on her current role as Digital Platform Manager. Jess holds a Master of Biomedical and Health Sciences from Monash University and is enthusiastic about increasing engagement across the healthtech industry.

Anastasia Daniels  
Assistant Event Coordinator  
Anastasia joined BioMelbourne Network in 2021. She is delighted to be a part of the team and has put her decade of experience and her Bachelor of Business with an events specialisation to good use. Anastasia also has a Diploma in Business Administration. She gained experience in coordinating a wide variety of events, including art festivals, sporting and charity events.

Emma Donnelly  
Strategic Project Manager  
Emma joined BioMelbourne Network in 2021 and brings more than 20 years of science communication, engagement and strategy experience to our organisation. She has worked for the Victorian Government, universities and not-for-profits. Emma has a passion for promoting engagement in science and supporting the healthtech sector to achieve this goal. Her engagement programs have won the Premier’s Science Awards and a Eureka Prize. Emma holds a Bachelor of Science, Post Graduate Diploma in Science and a Diploma from the University of Champagne-Ardenne.

James joined BioMelbourne Network in 2021. Originally from Perth, Western Australia, James holds a Bachelor of Commerce from Curtin University, where he majored in marketing and advertising. James brings a wealth of marketing and communications experience from his time working in the Australian, Canadian and the United Kingdom health and education sectors. Before joining BioMelbourne Network, James was Communications and Marketing Manager at the Australian Medical Association.

Jess joined BioMelbourne Network in 2021. Since then, she has worked across communications and strategic projects before taking on her current role as Digital Platform Manager. Jess holds a Master of Biomedical and Health Sciences from Monash University and is enthusiastic about increasing engagement across the healthtech industry.
In 2021–2022, we were fortunate to work with some passionate and capable biomedical students who joined the BioMelbourne Network team as interns. Thanks to the following interns for their incredible help.

Jess Balk  
Monash University  
Master of Biomedical and Health Sciences

Jordan Lawrence  
Deakin University  
Bachelor of Biomedical Science

Sharandeep Kaur Puwar  
Swinburne University of Technology  
Master of Science (Biotechnology)

Interning with BioMelbourne Network was a rewarding experience - an incredible team and a terrific introduction to the healthtech industry in Victoria. When I completed my internship, I was thrilled with the opportunity to work with BioMelbourne Network again in my current role as Digital Platform Manager.

Jess Balk  
Former Intern
BioMelbourne Network is the peak body in the Victorian healthtech industry, driving engagement and growth through local and international networks. Since 2001, we are actively fostering and growing an innovative, globally competitive sector and transforming our Network as well as the broader Victorian ecosystem.

Our members are diverse and experts in their respective fields, from early-career researchers to company executives and experienced directors, and start-ups through to large multinational corporations. We represent universities, researchers, manufacturers, government departments and the services sector, which includes commercialisation, product design and development, intellectual property, investment and legal sectors.

We are committed to maximising our value to the ecosystem through the delivery of our three-year strategic plan.

See our member directory

BioMelbourne Network Life Members

The Honourable John Brumby AO
Associate Professor Stella Clark AM
Michelle Gallaher
Dr Ashley Bates
Andrew Macdonald
Andrew Carter*

Professor David de Kretser AC
Tim Murphy
Professor David Penington AC
Dr John Raff
Janine Kirk AO
Alun Needham*

*Life memberships were awarded in November 2021
We commend the team at BioMelbourne Network for the way they have continued to evolve, whilst maintaining the focus on their members.

Brent McPherson
Manager Australia and New Zealand, World Courier (Aust) Pty Ltd
BioMelbourne Network launched our new three-year strategy in August 2021.

Here is an overview of some of our key initiatives, what we have accomplished and insights into our ongoing and future priorities.
## Strategic Priorities

### Strategies One, Two and Three

1. **Data and Insights**
   - Be the go-to source for the healthtech industry and Victorian Government for data and insights on sector potential, priorities and needs

2. **Identifying Opportunities**
   - Work with the healthtech industry to identify and prioritise strategic projects and working groups and advisory panels that support industry transformation and strengthening of the local innovation ecosystem

3. **Advocacy**
   - Be the peak body for the Victorian healthtech industry to build and maintain a supportive policy, regulatory and investment environment

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Data and Insights</th>
<th>Identifying Opportunities</th>
<th>Advocacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian Medtech Manufacturing Centre Collaboration</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Federal Patent: Box Regime development</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Manufacturing Industry Skills Alliance – IBSA Collaboration</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>GSK Boronia Site Redevelopment – Industry Reference Group</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Clinical Trials Action Plan – Steering Committee</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Parkville Precinct – Haymarket Roundabout Review</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Governor of Victoria Export Awards – International Health Category Sponsor</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>National Health and Medical Research Strategy 2022</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Monash Institute of Medical Engineering – Industry Advisory Committee</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Medtech Vic – Advisory Panel</td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Global Talent Visa</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
BioMelbourne Network has developed a strong collaboration with the Victorian Government’s Australian Medtech Manufacturing Centre (AMMC).

In the first half of the 2022 calendar year, the new AMMC team is working to deliver on their three strategic priorities:

1. grow local content into health procurement
2. build the competitive capability of Victorian medtech manufacturers
3. strengthen connections and collaboration across the sector.

Medtech manufacturers have identified multiple opportunities to improve capacity and collaboration in the sector, and to better connect manufacturers with medtech innovators. Through AMMC Partnerships funding, BioMelbourne Network will develop and run the first life sciences industry community platform - called Wilam - to facilitate collaboration and connection across the life sciences industry in Australia.

Wilam will focus on manufacturing topics of interest and bridge the gap between manufacturers and innovators. This initiative is a direct response from industry leaders requesting more contemporary approaches to collaborate and engage with peers. The new community platform will connect companies, researchers, supply chain partners and service providers, creating new collaboration and project opportunities and amplifying existing initiatives.

AMMC is partnering with Industry Capability Network Victoria to leverage a key role for purchasers of medtech products to identify new opportunities locally to address global supply chain vulnerabilities.
Clinical Trials Action Plan - Steering Committee

As part of the Victorian Health and Medical Research Strategy (2022-32), the Clinical Trials Action Plan has been established to lead reform for clinical trials in Victoria. The Clinical Trials Action Plan will develop a forward-thinking roadmap of priorities which will implement commitments from the Health and Medical Research Strategy. This will help secure Victoria’s position as a world leader in clinical research.

A Steering Committee has been established as an advisory group to the Clinical Trials Action Plan project, which is managed by the Office of Health and Medical Research (OHMR) and Department of Jobs, Precincts and Regions. It is composed of leaders and stakeholders across all areas involved in Victorian clinical trials, including government, rural and regional healthcare, researchers and clinicians, biotech and pharmaceutical companies, patient engagement and Indigenous health.

As an organisation supporting the research community, BioMelbourne Network is delighted to be a participating member of this Steering Committee.

The Clinical Trials Action Plan Steering Committee will provide oversight of the Clinical Trials Action Plan project, including advice on project direction. They will review project materials, highlight relevant organisational activities and/or interdependencies, and identify areas for consideration.

Advice from the Steering Committee will contribute to clinical trials reform that will improve health and economic outcomes here, and secure Victoria’s position as a world-leader in clinical research.
Strategy Four

**Healthtech Industry Development**

Deliver fee paying and sponsored initiatives that improve, strengthen and enhance the healthtech industry with our data, and industry engagement.

**Industry events and training**
- BioForum, BioSymposium, BioBusiness Insights
- Global Masterclasses
- Women in Leadership Awards
- Women’s Lunch
- CEO, CFO, NED Lunches

**Grow breadth and depth of network**
- Outreach across all of Victoria
- Improved support for early-mid career researchers
- Learning Lab – Events Library

**Improved BioMelbourne Network infrastructure**
- Wilam Life Sciences
- Industry Community

**Identify and fill training gaps**
- Medtech Victoria
- Futuremap assessments and roundtables

**Develop, maintain and leverage collaborative industry association relationships**
Wilam

BioMelbourne Network is undergoing a digital transformation to change how the life sciences industry connects, strengthens and grows.

In June 2022, we received an initial tranche of funding for development and implementation of our new Wilam Life Sciences Industry Community. This new digital platform will allow our ecosystem to engage and network in novel ways.

Wilam means home in Woi-wurrung language of the Wurundjeri people of the Kulin Nation, the traditional owners of the lands on which we are based. We extend our respect to all Aboriginal and Torres Strait Islander peoples throughout Australia. We pay our respects to their cultures, knowledge, and communities, to the Elders, past, present and emerging.

Wilam is a new digital platform for individuals and organisations in life sciences to come together in real time to have real conversations.

Through Wilam the ecosystem will connect, ask questions, access knowledge, network and participate in community-led groups. It will function as a catalyst for the life sciences industry to network in ways that fully leverage the new technologies available.

Wilam has discussion boards, tiered community and working groups, a searchable directory, library and an events calendar. It brings you networking, information, events, questions and resources that you’re interested in, to you.

Wilam is for manufacturers, researchers, service providers, universities, startups, SMEs and global enterprises.

With you, we are building Wilam, a living database and new virtual home for the Australian life sciences industry. Join your community today.

Learning Lab

Since the start of the COVID-19 pandemic, we have been recording all our events, whether fully virtual or hybrid events. We have received funding to build an online home for our library of events so they can be watched on demand.

Watch this space.

AMMC is excited to be partnering with BioMelbourne Network to strengthen connectivity and collaboration and bridge the gap between medtech innovators and manufacturers. We see great potential in the new medtech connections that Wilam will facilitate, through its virtual platform and convening of forums on manufacturing topics of interest.

Shelley Jackson
Director, AMMC

Register, sign up and watch our promotional video.

Go to wilam.com
## Strategy Five - Sector Promotion

5 Sector Promotion

Be a gateway for global markets, helping to build awareness of the Victorian healthtech industry domestically and overseas.

<table>
<thead>
<tr>
<th>Sector business development and support</th>
<th>Improve the profile and awareness of BioMelbourne Network</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Victoria - Virtual Trade Mission Singapore</td>
<td>Promotional sponsored webinars</td>
</tr>
<tr>
<td>Promotional sponsored webinars</td>
<td>Regular updates to members and the Victorian Government on our strategy and initiatives</td>
</tr>
<tr>
<td>Pfizer/mRNA Victoria Research Connect Symposium</td>
<td>Increase awareness across other ecosystems domestically and internationally</td>
</tr>
<tr>
<td></td>
<td>Promotional and advertising opportunities</td>
</tr>
<tr>
<td></td>
<td>Global Victoria - Webinar and video series</td>
</tr>
</tbody>
</table>
Singapore/APAC Trade Mission

As a trade alliance partner with Global Victoria, BioMelbourne Network is leading a trade mission to Singapore, targeting the export services sector across the medtech translation and commercialisation space.

We thank the Victorian Government and Global Victoria for their support of this initiative which was funded and planned in 2021-2022 but delayed due to COVID.

Highlights:
- Three virtual events plus inclusion in the SWITCH conference in October 2022 in Singapore
- At the SWITCH conference, Jeff Malone will lead a panel discussion on the strengths of the medtech ecosystem and facilitate networking and partnering sessions
- We will leverage the WILAM community platform to create an ongoing connection between the two trade ecosystems.
Global Victoria’s network of 23 trade and investment offices connects Victorian exporters with international buyers and business leaders, and provides high-level market intelligence, insights and guidance. This invaluable support helps our exporters be competitive in global markets.

BioMelbourne Network was engaged to produce a series of podcasts and a promotional sector video to be used during conferences with Global Victoria and the Victorian Government trade and investment network. These podcasts showcase the expertise and opportunities that exist within the globally competitive Victorian healthtech industry. These digital media resources allow many organisations to showcase our skills and capabilities around the world - which wasn’t possible during the COVID-19 pandemic.

We have produced podcasts on these themes:

- regenerative medicine
- oncology
- infectious diseases
- neurosciences
- cardiovascular health
- clinical trials
- genomics.

Many thanks to Global Victoria and Dr Megan Robertson who generously hosted this podcast series.
Building our Events Program

BioMelbourne Network hosts an annual program of events, including multi-day global masterclasses, webinars and seminars, conferences, information sessions and peer-to-peer events for Non-Executive Directors, CFOs and CEOs. These are designed to provide insights and updates to the healthtech industry and are a forum for members to showcase their skills and experience.

We address key issues and provide information across the diverse sectors that we represent, including academia and research, commercialisation and business, pharmaceuticals and biotechnology, medical technology, digital health and more. We also provide opportunities for attendees to engage with peers and share knowledge at roundtables and industry engagement functions.

We design our events with industry input from members, partners and the Victorian Government. In this collaborative approach, our stakeholders donate their time and expertise to event planning while we can leverage our position to attract leading subject matter experts to speak at our events.

BioMelbourne Network members, the Victorian Government and other partners also provide valuable sponsorship, which allows us to host relevant events for you, and at same time promote some of the terrific organisations that support us through the process.

We thank everyone who has contributed to the success of our events program and welcome your input and insights as we develop our future events.

“Congratulations to BioMelbourne Network for the outstanding Environmental, Social and Governance roundtable, and to KPMG Australia for their support and expertise.”
BioMelbourne Network thanks the following sponsors for supporting us throughout the year and making our events and activities possible.

**Premier Sponsors**

- Allens
- Biointelect
- Bosch Australia Manufacturing Solutions
- Brooker Consulting
- Cytiva
- Emerson
- Fundsquire
- Gadens
- Hemideina
- Honan Insurance Group
- MedTechVic and Factory of the Future
- mexec
- mRNA Victoria
- Nucleus Network
- Phillips Ormonde Fitzpatrick
- Prime Accounting and Business Advisory Pty Ltd
- SeerPharma Pty Ltd
- Starpharma
- The Migration Agency
- Walter and Eliza Hall Institute of Medical Research

**Major Sponsors and Partners**

- AVATAR
- Biointelect
- Global Victoria
- mRNA Victoria
- Nucleus Network
- Phillips Ormonde Fitzpatrick
- Prime Accounting and Business Advisory Pty Ltd
- SeerPharma Pty Ltd
- Starpharma
- The Migration Agency
- Walter and Eliza Hall Institute of Medical Research
Events Statistics

Number of speakers: 156
Total events: 33
Online events: 23
Total attendees: 4,545 (60% increase on 2021)

Number of international speakers: 15
Female speakers: 1,016

Number of companies represented: ✔️ ✔️ ✔️ ✔️ ✔️
Event Timeline

CEO, CFO, NED ROUNDTABLES
22 July 2021
Non-Executive Director Roundtable: The New Face of Corporate Culture and Risk

PHARMA AND BIOTECH
ACADEMIA AND RESEARCH
4 August 2021
BioForum: Our Mental Health Epidemic - The Need for Innovation in Treatment

PHARMA AND BIOTECH
COMMERCIALISATION
ACADEMIA AND RESEARCH
10 August 2021
BioForum: Future Direction for mRNA Technology

SECTOR ENGAGEMENT
12 August 2021
BioMelbourne Network Strategy Launch: The Path Forward

MEDTECH AND HEALTH IT
8 November 2021
MedTechVic futuremap® workshop

BUSINESS AND FINANCIAL
4 November 2021
Industry Report – Assessing Pandemic Impact on Freight and Logistics for the Victorian Healthtech Industry

COMMERCIALISATION
ACADEMIA AND RESEARCH
14 October 2021
Is Your Biologic Molecule Trapped on the Bench?

BUSINESS AND FINANCIAL
6 October 2021
Increasing Business and Research Partnerships with Israel: Opportunities, Funding and In-Market Support

PHARMA AND BIOTECH
COMMERCIALISATION
ACADEMIA AND RESEARCH
3 September 2021
BioSymposium: Advancements in Precision Medicine – Opportunities, Challenges and Economics

Find out more

Find out more

Find out more

Find out more

Find out more
### Event Timeline

**BUSINESS AND FINANCIAL**  
10 March 2022  
*Automating Document, Trial and Quality Management: Software Application for Healthtech*  
Find out more

**MEDTECH AND HEALTH IT**  
10 March 2022  
*MedTechVic futuremap® Workshop - Bairnsdale*  
Find out more

**MEDTECH AND HEALTH IT**  
11 March 2022  
*MedTechVic futuremap® Workshop - Sale*  
Find out more

**PHARMA AND BIOTECH**  
22 March 2022  
*BioForum: Translating Innovation - From Lab Bench to Marketplace*  
Find out more

**PHARMA AND BIOTECH**  
23 March 2022  
*BioPharma Masterclass: Creating a Value Story for Your Product*  
Find out more

**SECTOR ENGAGEMENT**  
5 May 2022  
*2022 Women in Leadership Awards Ceremony*  
Find out more

**BUSINESS AND FINANCIAL**  
13 April 2022  
*2022 Industry Update – Investment and Funding*  
Find out more

**MEDTECH AND HEALTH IT**  
5 April 2022  
*BioSymposium: Optimising the Victorian Medtech Sector*  
Find out more

**MEDTECH AND HEALTH IT**  
1 April 2022  
*MedTechVic futuremap® Workshop - Emerson Manufacturing Site*  
Find out more

**PHARMA AND BIOTECH**  
30 March 2022  
*Biotech Innovations – A BioChallenge Winner Showcase*  
Find out more
Event Timeline

SECTOR ENGAGEMENT
13 May 2022
Connecting Women Lunch
Find out more

PHARMA AND BIOTECH
BUSINESS AND FINANCIAL
24 May 2022
BioForum: Exploring the IPO Landscape – Biotech Boom, Bubble or Bust?
Find out more

PHARMA AND BIOTECH
BUSINESS AND FINANCIAL
25 May 2022
BioPharma Masterclass: The Art of Capital Raising – Negotiating the Investment Landscape
Find out more

MEDTECH AND HEALTH IT
24 June 2022
MedTechVic futuremap® Workshop – Bosch Australia Manufacturing Solutions, Clayton
Find out more

PHARMA AND BIOTECH
10 June 2022
BioForum: Flu Resurgence – What does this mean for our sector?
Find out more

PHARMA AND BIOTECH
COMMERCIALISATION
ACADEMIA AND RESEARCH
8-9 June 2022
mRNA Victoria and Pfizer Symposium: Australian Showcase of RNA Technology and Therapeutics Research
Find out more

Event Themes

ACADEMIA AND RESEARCH

BUSINESS AND FINANCIAL

CEO, CFO, NON-EXECUTIVE DIRECTOR ROUNDTABLES

COMMERCIALISATION

MEDTECH AND HEALTH IT

PHARMA AND BIOTECH

SECTOR ENGAGEMENT
BioSymposium: Optimising the Victorian Medtech Ecosystem

BioMelbourne Network brought together experts from medtech, research and commercialisation to discuss Victoria’s translation and commercialisation ecosystem, its strengths and weaknesses, and how it is supported.

BioMelbourne Network CEO, Jeff Malone said that the event presented the first comprehensive analysis of Victoria’s medtech translation and commercialisation landscape, proving that Victoria has the skills and capabilities needed for a world class ecosystem.

“This can be overwhelming but over four sessions the event speakers held our hands and simplified the process from concept to commercialisation,” he said.

“We also heard real world case studies from medtech companies who have taken the translation leap and succeeded.”

The enthusiasm of the speakers for the sector was evident. It was a great opportunity and a well laid out session.

Really interesting presentations and discussion. I enjoyed listening to the variety of topics and perspectives.
Events in Focus

2022 BioMelbourne Network Connecting Women Lunch

“At the BioMelbourne Network event, successful women in medtech shared stories of support and perseverance, and how diversity of experience brings us closer together.”

Jesssica Rosa
Biotechnology Manufacturing Assistant, CSL

Left to right: Dr Kerry Hegarty, Dr Emma Ball, George Kenley and Jill Allen.
Connecting Women Lunch: The Power of Meaningful Relationships

Jessica Rosa, from CSL Behring, attended an inspirational BioMelbourne Network event for women working in the biotech and medtech industries. Here is her reflection.

The BioMelbourne Network’s Connecting Women Lunch, which was held on 13 May 2022, marked its 12th anniversary. It was an honour to be back this year as a guest and see women celebrated for their achievements within the Victorian biotechnology sector.

CSL showcased three Everyday Trailblazers, highlighting what drives and inspires them. Simone Ruedin (Product Support Coordinator), Genevieve Martin-Roussety (Scientist) and Jill Allen (Senior Director of Bulk Manufacturing) are pioneering individuals who take calculated risks to create new paths and encourage future leaders to follow in their footsteps. These women also use their passions to fuel their creative minds and innovate with a patient-focused attitude. As a CSL employee, I am inspired by these trailblazers and proud to work with such incredible talent.

The keynote speaker of the afternoon was Dr Ranjana Srivastava OAM, an oncologist and award-winning writer. She discussed how essential human connection is, particularly during the COVID-19 pandemic.

Dr Srivastava recounted a powerful story about a relationship that left a permanent mark on her personally and professionally. She spoke of the importance of relationships and how they have the power to leave a remarkable impression on people. That no matter how prestigious a title, the ability to make time for people is a true gift. Dr Srivastava also said that ambition can co-exist with humility, and that being present can heal more than a few simple words. Her speech was moving, heartfelt and inspirational.

Afterwards, Dr Emma Ball (Head of Illumina for Startups Australia), George Kenley (Seer Cofounder and Chief Operating Officer) and Jill Allen joined the On the Couch segment. Moderated by Dr Kerry Hegarty (Incisive Technologies Director and CEO), each woman shared their story. Their message was emphatic: take advantage of every opportunity presented and aspire to achieve greatness.

I left the Connecting Women Lunch thinking of Dr Srivastava’s parting words: “Go forth with something to do, someone to love and something to look forward to in the future.”
We are in the seventh year of these awards which have shone a much needed and really important, well-deserved spotlight on these remarkable women who are doing remarkable things in our healthtech sector. It shows both what talent we have here, but also serves as a reminder about why we need to continue to elevate women’s voices across all areas of endeavour, including biotech.

The Honourable Jaala Pulford
Minister for Innovation, Medical Research and the Digital Economy

As a passionate advocate for Australia’s vibrant biotech industry, I am thrilled to receive this prestigious award and participate in the pinnacle event for our sector, The Connecting Women Lunch. I thank BioMelbourne Network for acknowledging and celebrating the contributions of the many fabulous women working in this field.

Dr Emma Ball
Head of Illumina for Startups Australia, Illumina

I was honoured to be awarded the 2022 Emerging Leader Award from BioMelbourne Network. Thank you for supporting women leaders through this program. In addition to the recognition of the work I and my team do in the field of vision restoration, the award has already led to new research collaborations and important networking opportunities.

Associate Professor Lauren Ayton
NHMRC Emerging Leader Investigator and Driving Research Momentum Fellow, The University of Melbourne and the Centre for Eye Research Australia

“
2022 BioMelbourne Network
Women In Leadership Awards

Our award winners

Distinguished Leadership Award
Dr Emma Ball
Head of Illumina for Startups Australia, Illumina

Emerging Leadership Award
Associate Professor Lauren Ayton
NHMRC Emerging Leader Investigator and Driving Research Momentum Fellow, The University of Melbourne and the Centre for Eye Research Australia

Inspiring Leadership Award
George Kenley
Co-Founder and Chief Operating Officer, Seer
Industry Events Provide Valuable Training

BioMelbourne Network runs an annual program of events for our diverse membership across the life sciences industry.

Dr Catherine Osborne, CEO at Crux Biolabs, said that the networking and professional development opportunities that BioMelbourne Network creates are invaluable.

“Our service business, Crux Biolabs, has been able to grow and our staff have learnt so much at the events and programs organised by BioMelbourne Network,” she said.

“Highlights from the past year include two major panel and networking events at ACMI, the Marlow Hampshire management course and of course, the return of the Connecting Women in Biotech Lunch, a highlight in the Melbourne biotech calendar.”

Dr Catherine Osborne
Chief Executive Officer,
Crux Biolabs

Expanding mRNA Research through Global Collaboration

Recently, BioMelbourne and mRNA Victoria co-hosted an mRNA Victoria and Pfizer symposium, which showcased Australian mRNA and RNA research to a diverse audience, paving the way for new collaborations.

“At Pfizer, we recognise that global collaboration is critical to advancing cutting-edge science that could change patients’ lives, including the use of mRNA,” said Dr Anand Gautam, Pfizer Executive Director and Emerging Science Lead (Asia and Asia-Pacific).

“mRNA technology presents a unique opportunity to develop a new class of potentially breakthrough medicines, and Australian scientists are contributing greatly to mRNA research. Pfizer is committed to supporting their efforts through initiatives like the mRNA Victoria and Pfizer symposium, which was meaningfully enabled by BioMelbourne Network.”

As part of their commitment to advancing the field, Pfizer has joined with mRNA Victoria to give an outstanding Victorian-based, early-career researcher the opportunity to spend nine months performing research in the US at Pfizer labs with its RNA Accelerator.

“We look forward to the potential for future initiatives designed to help Australian science flourish, such as our Fellowship program for mRNA researchers,” Dr Gautam said.

Dr Anand Gautam
Executive Director and Emerging Science Lead (Asia and Asia-Pacific), Pfizer
Member Testimonials

Sector Support Vital during COVID-19 Pandemic

As part of its three-year strategy, BioMelbourne Network is becoming an agile organisation and pivoting to the needs of members.

Brent McPherson, Manager Australia and New Zealand at World Courier, valued this flexibility as a transporter of temperature sensitive goods to global clients.

“We commend the BioMelbourne Network team for their inclusive approach towards members which is key to their success,” he said.

“They are enabling us to support the sector throughout the COVID-19 pandemic and global supply chain issues. It’s a strong partnership which we truly value.”

As part of that support, BioMelbourne Network held hybrid events in 2021-2022, making it possible for local, interstate and international members to attend virtually when travel was restricted.

Brent said: "The networking events are a key part of our involvement, which helps us stay connected with the industry;"

Brent McPherson
Manager Australia and New Zealand,
World Courier (Aust) Pty Ltd

Connecting the Ecosystem Globally

A key priority of BioMelbourne Network is engaging with our members and facilitating global relationships.

First Ascent Biomedical based in the US, is one such company to benefit from new connections with Melbourne leaders working in cancer research, education and patient care.

Dr Noah Berlow, Chief Technology Officer, First Ascent Biomedical, said that by joining BioMelbourne Network it was possible to work through the Australian ecosystem from the outside, and reach key people in Melbourne - which is the epicentre of medical and biotech advancements in Australia.

"As BioMelbourne Network members, we could build a footprint in the Australian medical ecosystem and find the right partners to help deliver our personalised cancer therapy platform," he said.

"BioMelbourne Network helped us connect with leaders at Peter MacCallum Cancer Centre and the VCCC Alliance. These connections have been invaluable for our company and helped us prepare for our recent conversation with Breakthrough Victoria."

Dr Noah Berlow
Chief Technology Officer,
First Ascent Biomedical
BioMelbourne Network would like to thank Blue Vapours for their assistance in the production of this document.